NeuroOne Medical Technologies Corporation announced the appointment of Jason Mills to its Board of Directors, effective December 18, 2025. Mills currently serves as Executive Vice President of Strategy at NYSE-listed Penumbra, Inc., where he leads long-range planning, FP&A, Business Development, and Investor Relations. Penumbra is the world's leading thrombectomy company, focused on developing innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism, and acute limb ischemia. Prior to joining Penumbra, Mills was a dedicated med-tech investment analyst for more than two decades, holding the role of Managing Director and head of the medical technology equity research practice at Canaccord Genuity for over 13 years. During his tenure, he prepared financial models and forecasts, published research, and conducted due diligence on dozens of public and private companies in the sector. He has earned awards for his equity research, including being ranked #2 Medical Devices analyst in The Wall Street Journal's 2011 'Best on the Street' Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts.
Dave Rosa, CEO of NeuroOne, stated, "We are privileged to welcome Jason to NeuroOne with his strong background in med-tech in both corporate settings and as an industry investment analyst. Having known Jason since he was at Canaccord, I know he brings unparalleled and invaluable experience and insights in med-tech. His firsthand knowledge of our industry, combined with his investment and capital markets expertise, will be a critical resource as we progress on our clinical and corporate goals." Paul Buckman, Chairman of the Board of Directors, added, "In addition to his service on the Compensation and Nominating & Corporate Governance Committees, Jason will help us expand the breadth and depth of our reach as a company transforming the diagnosis and treatment of neurological disorders, positioning us to create additional value for our shareholders."
This appointment matters because it strengthens NeuroOne's strategic direction at a critical juncture. Mills' dual expertise as both a seasoned med-tech analyst and a current executive at a leading medical device company like Penumbra provides NeuroOne with unique insights into market dynamics, investor expectations, and corporate strategy. His experience in financial modeling, due diligence, and capital markets will be invaluable as NeuroOne advances its clinical programs and seeks to create shareholder value. The company is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. For more information, visit nmtc1.com.
The implications of this board appointment are significant for NeuroOne's future trajectory. Mills' industry relationships and analytical background can help the company better navigate regulatory pathways, identify potential partnership or acquisition opportunities, and communicate its value proposition to the investment community. His role on key committees like Compensation and Nominating & Corporate Governance suggests he will influence corporate governance practices and executive compensation strategies, aligning them with industry standards and shareholder interests. As NeuroOne pursues applications in areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence, Mills' strategic vision could help prioritize these initiatives based on market potential and clinical feasibility. This move signals NeuroOne's commitment to bolstering its leadership with individuals who have proven track records in both analyzing and operating within the competitive med-tech landscape, potentially enhancing the company's credibility and strategic execution as it aims to transform neurological disorder treatments.
